YCANTH Revenue Jumps 57.9% to $5.7M as Verrica Secures $27.5M Growth Capital
VRCA sits 20% above its 52-week low of $3.08.
Summary
Verrica reported Q3 2026 YCANTH net product revenue of $5.7M, up 57.9% year over year and 11.9% from the prior quarter, with total revenue of $6.9M. The company also unlocked access to $27.5M in growth capital and says cash now funds operations through both common-warts Phase 3 trial readouts. That matters because the last 10-Q carried a going concern warning and a $13.2M quarterly net loss, so the financing plus revenue ramp directly addresses the survival question. The first pivotal common-warts trial (COVE-2) has completed enrollment, with topline data expected Q1 2027 and the second trial's data mid-2027. Watch those readouts — they are the binary events for the equity.
At the time of this announcement, VRCA was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $63.9M. The 52-week trading range was $3.08 to $9.82. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.